SCHEMBL20913892

SCHEMBL20913892

CC(=O)Nc1cccc2nc(-c3c(C)[nH]c4c(-c5ccccc5)c(C(F)(F)F)nn4c3=O)[nH]c12

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 3/20 0.40
▸ ALDH1A1 P00352 3/20 0.40
▸ KMT2A Q03164 3/20 0.40
▸ POLB P06746 2/20 0.40
▸ L3MBTL1 Q9Y468 1/20 0.40
▸ KDM4E B2RXH2 3/20 0.38
▸ FGFR1 P11362 1/20 0.36
▸ FGFR2 P21802 1/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.36
▸ LMNA P02545 2/20 0.35
▸ ARF6 P62330 1/20 0.35
▸ MAT2A P31153 1/20 0.34
▸ ERCC1 P07992 1/20 0.34
▸ FEN1 P39748 1/20 0.34
▸ ERCC4 Q92889 1/20 0.34
▸ PSD A5PKW4 2/20 0.34
▸ MMP2 P08253 1/20 0.33
▸ MMP9 P14780 1/20 0.33
▸ COMT P21964 1/20 0.33
▸ MMP8 P22894 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20914271 0.84 KDM4E (0.39) MEN1ALDH1A1KMT2APOLBL3MBTL1
SCHEMBL20914113 0.81 KDM4E (0.45) MEN1ALDH1A1KMT2APOLBKDM4E
SCHEMBL20913938 0.80 TNKS (0.50) ALDH1A1POLBKDM4EMAPT
SCHEMBL20914404 0.80 POLB (0.44) MEN1ALDH1A1KMT2APOLBL3MBTL1
SCHEMBL20913971 0.78 POLB (0.45) MEN1ALDH1A1KMT2APOLBL3MBTL1
SCHEMBL20914262 0.76 TNKS (0.39) ALDH1A1POLBKDM4ESMN1; SMN2CDK4
SCHEMBL20914122 0.75 KDM4E (0.43) MEN1ALDH1A1KMT2APOLBL3MBTL1
SCHEMBL20914305 0.74 POLB (0.43) MEN1ALDH1A1KMT2APOLBL3MBTL1
SCHEMBL20914410 0.73 POLB (0.46) MEN1ALDH1A1KMT2APOLBL3MBTL1
SCHEMBL20819029 0.73 POLB (0.47) MEN1ALDH1A1KMT2APOLBL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10738056-B2 Pyrazolopyrimidinone compounds and uses thereof ADURO BIOTECH INC. (US) 2020-08-11 — — US disclosed
US-10738056-B2 Pyrazolopyrimidinone compounds and uses thereof ADURO BIOTECH INC. (US) 2020-08-11 — — US disclosed
US-20190119285-A1 PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF CHINOOK THERAPEUTICS, INC. 2019-04-25 — — US disclosed
US-20190119285-A1 PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF CHINOOK THERAPEUTICS, INC. 2019-04-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10738056-B2 Pyrazolopyrimidinone compounds and uses thereof NLRP3, NLRP1, P2RX7 MEN1 2785/4885ALDH1A1 1246/4885KMT2A 3490/4885
US-20190119285-A1 PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF NLRP3, NLRP1, P2RX7 MEN1 2785/4885ALDH1A1 1246/4885KMT2A 3490/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback